Riverside Promotes Borden To Partner

Riverside Partners has promoted Philip Borden to general partner. He joined the firm in 2005, before which he spent time at both Oxford Bioscience Partners and Frazier Healthcare Ventures. 



Riverside Partners, a leading healthcare and technology focused private equity firm, today announced the promotion of Philip Borden to General Partner.  Since joining the firm as a Principal in early 2005, Philip has focused on investing opportunities in the healthcare area, including medical technology and equipment, healthcare services, outsourced manufacturing, and healthcare tools and diagnostics.  Philip has spent his entire career in healthcare private equity and has been instrumental in many of Riverside’s recent healthcare investments.  Prior to joining Riverside, Philip served as an investment professional at Oxford Bioscience Partners and Frazier Healthcare Ventures.  He holds a Bachelor of Science degree in Cell and Molecular Biology from Duke University, with honors, and a Master of Business Administration from Harvard Business School, where he graduated with highest distinction as a Baker Scholar.  


 “Over the past four years, Philip’s deep experience in healthcare investing has been extremely valuable to the firm and to our portfolio companies.  We are excited about Philip expanding his role as a leader within the firm for many years to come,” said David Belluck, a Riverside General Partner.



About Riverside Partners 

Founded in 1989, Riverside Partners is a middle market private equity firm currently investing Riverside Fund III, L.P.  The fund focuses on growth-oriented companies in the healthcare and technology industries.  Riverside is particularly experienced at partnering with founders, owners and management teams and it brings substantial domain expertise and operating experience to its portfolio companies.  The partners at Riverside have managed more than $500 million in investments in over 50 companies.  The firm is currently focused on companies with revenues between $20 – $200 million and with $5 – $25 million of EBITDA.